Get the Stockscreener App
2.05
1.49%
0.03
After Hours:
2.05
Medicinova Inc stock is traded at $2.05, with a volume of 37,842.
It is up +1.49% in the last 24 hours and down -2.84% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$2.02
Open:
$2.02
24h Volume:
37,842
Relative Volume:
0.52
Market Cap:
$100.54M
Revenue:
-
Net Income/Loss:
$-9.51M
P/E Ratio:
-10.79
EPS:
-0.19
Net Cash Flow:
$-10.96M
1W Performance:
+6.22%
1M Performance:
-2.84%
6M Performance:
+56.49%
1Y Performance:
+45.39%
1-Day Range:
$2.0002
$2.05
1-Week Range:
$1.89
$2.05
52-Week Range:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
2.05 | 100.54M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Geode Capital Management LLC - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Zacks sees 400% upside for MediciNova amid incoming damages from Sanofi/Novartis dispute - Kursiv Media
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement - Smartkarma
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement… - MSN
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - The Manila Times
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - Darien Times
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):